Published April 2020
| Version v1
Journal article
HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort)
- Others:
- Universidade de Brasilia [Brasília] (UnB)
- Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD) ; Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA)
- Département d'hépatologie [CHU Cochin] ; Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Physiopathologie du système immunitaire (Inserm U1223) ; Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Université Sorbonne Paris Cité (USPC)
- Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC) ; Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Hôpital de la Croix-Rousse [CHU - HCL] ; Hospices Civils de Lyon (HCL)
- Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL) ; Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Bordeaux population health (BPH) ; Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- CIC Bordeaux ; Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Service d'information Médicale [CHU de Bordeaux] (Pôle de Santé Publique) ; CHU Bordeaux [Bordeaux]
- Hôpital l'Archet
- Laboratoire Motricité Humaine Expertise Sport Santé (LAMHESS) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université de Toulon (UTLN)-Université Côte d'Azur (UCA)
- CHU Bordeaux [Bordeaux]
- Service Maladies infectieuses et tropicales [AP-HP Hôpital Cochin] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- ANRS CO13 HEPAVIH Study Group: D Salmon, L Wittkop, P Sogni, L Esterle, P Trimoulet, J Izopet, L Serfaty, V Paradis, B Spire, P Carrieri, M A Valantin, G Pialoux, J Chas, I Poizot-Martin, K Barange, A Naqvi, E Rosenthal, A Bicart-See, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Vittecoq, D Neau, P Morlat, F Bani-Sadr, L Meyer, F Boufassa, S Dominguez, B Autran, A M Roque, C Solas, H Fontaine, D Costagliola, L Piroth, A Simon, D Zucman, F Boué, P Miailhes, E Billaud, H Aumaître, D Rey, G Peytavin, V Petrov-Sanchez, A Pailhé, D Salmon, R Usubillaga, P Sogni, B Terris, P Tremeaux, C Katlama, H Stitou, Y Benhamou, F Charlotte, S Fourati, A Simon, P Cacoub, S Nafissa, I Poizot-Martin, O Zaegel, H Laroche, C Tamalet, G Pialoux, J Chas, P Callard, F Bendjaballah, C Le Pendeven, B Marchou, L Alric, S Metivier, J Selves, F Larroquette, E Rosenthal, A Naqvi, V Rio, J Haudebourg, M C Saint-Paul, C Partouche, O Bouchaud, M Ziol, Y Baazia, M Uzan, D Garipuy, M J Ferro-Collados, F Nicot, Y Yazdanpanah, H Adle-Biassette, G Alexandre, C Lascoux-Combe, J M Molina, P Bertheau, M L Chaix, C Delaugerre, S Maylin, J Bottero, J Krause, P M Girard, D Wendum, P Cervera, J Adam, C Viala, C Goujard, Y Quertainmont, E Teicher, C Pallier, D Vittecoq, O Lortholary, C Rouzaud, J Lourenco, F Touam, C Louisin, V Avettand-Fenoel, A Mélard, D Neau, A Ochoa, E Blanchard, S Castet-Lafarie, C Cazanave, D Malvy, M Dupon, H Dutronc, F Dauchy, L Lacaze-Buzy, P Bioulac-Sage, S Reigadas, P Morlat, D Lacoste, F Bonnet, N Bernard, M Hessamfar, F Paccalin, C Martell, M C Pertusa, M Vandenhende, P Merciéer, T Pistone, M C Receveur, M Méchain, P Duffau, C Rivoisy, I Faure, S Caldato, J L Pellegrin, J F Viallard, E Lazzaro, C Greib, D Zucman, C Majerholc, E Farfour, F Boué, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez, C Deback, Y Lévy, J D Lelièvre, A S Lascaux, G Melica, E Billaud, F Raffi, C Allavena, V Reliquet, D Boutoille, C Biron, A Rodallec, L Le Guen, P Miailhes, D Peyramond, C Chidiac, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri, C Scholtes, T T Le-Thi, P Chavanet, M Duong Van Huyen, M Buisson, A Waldner-Combernoux, S Mahy, R Binois, A L Simonet-Lann, D Croisier-Bertin, H Aumaître, F Bani-Sadr, D Lambert, Y Nguyen, J L Berger, D Rey, M Partisani, M L Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, P Gantner, S Fafi-Kremer, G Peytavin, F Roustant, I Kmiec, L Traore, S Lepuil, S Parlier, V Sicart-Payssan, E Bedel, C Louisin, M Mole, C Bolliot, M Mebarki, A Adda-Lievin, F Z Makhoukhi, O Braik, R Bayoud, M P Pietri, V Le Baut, D Bornarel, C Chesnel, D Beniken, M Pauchard, S Akel, S Caldato, C Lions, L Chalal, Z Julia, H Hue, A Soria, M Cavellec, S Breau, A Joulie, P Fisher, C Ondo Eyene, S Ogoudjobi, C Brochier, V Thoirain-Galvan, E Boerg, V Conte, L Dequae-Merchadou, M Desvallees, N Douiri, L Esterle, C Gilbert, S Gillet, R Knight, F Marcellin, L Michel, M Mora, C Protopopescu, P Roux, S Tezkratt, I Yaya, T Barré, T Rojas Rojas, V Villes, M Baudoin, M Santos
Description
Mortality among individuals co-infected with HIV and hepatitis C virus (HCV) is relatively high. We evaluated the association between psychoactive substance use and both HCV and non-HCV mortality in HIV/HCV co-infected patients in France, using Fine and Gray's competing-risk model adjusted for socio-demographic, clinical predictors and confounding factors, while accounting for competing causes of death. Over a 5-year median follow-up period, 77 deaths occurred among 1028 patients. Regular/daily cannabis use, elevated coffee intake, and not currently smoking were independently associated with reduced HCV-mortality (adjusted sub-hazard ratio [95% CI] 0.28 [0.10-0.83], 0.38 [0.15-0.95], and 0.28 [0.10-0.79], respectively). Obesity and severe thinness were associated with increased HCV-mortality (2.44 [1.00-5.93] and 7.25 [2.22-23.6] versus normal weight, respectively). Regular binge drinking was associated with increased non-HCV-mortality (2.19 [1.10-4.37]). Further research is needed to understand the causal mechanisms involved. People living with HIV/HCV co-infection should be referred for tobacco, alcohol and weight control interventions and potential benefits of cannabis-based therapies investigated.
Abstract
International audience
Additional details
- URL
- https://www.hal.inserm.fr/inserm-03012682
- URN
- urn:oai:HAL:inserm-03012682v1
- Origin repository
- UNICA